Literature DB >> 2818107

Incomplete lupus erythematosus.

J M Greer1, R S Panush.   

Abstract

Thirty-eight patients with incomplete lupus erythematosus (ILE) (defined as the presence of fewer than four of the criteria of the American College of Rheumatology for systemic lupus erythematosus [SLE]) were identified and compared with 42 patients with SLE. Both groups were comparable with respect to age, sex, and race. Patients with ILE had symptoms for an average of 38 months before seeking rheumatologic care and were followed up for a mean of 19 months; patients with SLE averaged 9 months with symptoms before their diagnosis was made and were followed for a mean of 30 months. Characteristic clinical features of patients with ILE included positive antinuclear antibody titers (83%), polyarticular nonerosive arthritis (47%), and cutaneous findings (61%). These were comparable with findings in the the SLE group. However, patients with ILE had significantly fewer systemic manifestations than did those with SLE. Patients with ILE were treated with nonsteroidal anti-inflammatory drugs more frequently (47%) than were patients with SLE, while the latter group received more topical and oral corticosteroids and immunosuppressives. Only two of the patients with ILE went on to have typical SLE. Thus, ILE may be frequent, mild, and relatively stable or benign, apparently evolving slowly if at all into SLE or other rheumatic disease.

Entities:  

Mesh:

Year:  1989        PMID: 2818107

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  16 in total

Review 1.  Preclinical systemic lupus erythematosus.

Authors:  Julie M Robertson; Judith A James
Journal:  Rheum Dis Clin North Am       Date:  2014-09-02       Impact factor: 2.670

2.  Diagnostic uncertainty and epistemologic humility.

Authors:  Andrew Kelly; Richard S Panush
Journal:  Clin Rheumatol       Date:  2017-04-22       Impact factor: 2.980

3.  We need better classification and terminology for "people at high risk of or in the process of developing lupus".

Authors:  Karen H Costenbader; Peter H Schur
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-05       Impact factor: 4.794

4.  Screening characteristics for enrichment of individuals at higher risk for transitioning to classified SLE.

Authors:  K A Young; M E Munroe; J M Guthridge; D L Kamen; G S Gilkensen; J B Harley; M H Weisman; D R Karp; D J Wallace; J A James; J M Norris
Journal:  Lupus       Date:  2019-03-07       Impact factor: 2.911

Review 5.  Preclinical lupus.

Authors:  Rebecka Bourn; Judith A James
Journal:  Curr Opin Rheumatol       Date:  2015-09       Impact factor: 5.006

6.  Clinical and Serologic Features in Patients With Incomplete Lupus Classification Versus Systemic Lupus Erythematosus Patients and Controls.

Authors:  Teresa Aberle; Rebecka L Bourn; Melissa E Munroe; Hua Chen; Virginia C Roberts; Joel M Guthridge; Krista Bean; Julie M Robertson; Kathy L Sivils; Astrid Rasmussen; Meghan Liles; Joan T Merrill; John B Harley; Nancy J Olsen; David R Karp; Judith A James
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-11-14       Impact factor: 4.794

Review 7.  Biomarkers in rheumatic diseases: how can they facilitate diagnosis and assessment of disease activity?

Authors:  Chandra Mohan; Shervin Assassi
Journal:  BMJ       Date:  2015-11-26

Review 8.  Autoantibodies and SLE: the threshold for disease.

Authors:  Nancy J Olsen; David R Karp
Journal:  Nat Rev Rheumatol       Date:  2013-12-03       Impact factor: 20.543

Review 9.  Pathogenesis and prevention of rheumatic disease: focus on preclinical RA and SLE.

Authors:  Kevin D Deane; Hani El-Gabalawy
Journal:  Nat Rev Rheumatol       Date:  2014-02-11       Impact factor: 20.543

10.  Undifferentiated connective tissue diseases-related hepatic injury.

Authors:  Ying Zhang; Fu-Kui Zhang; Xiao-Ning Wu; Tai-Ling Wang; Ji-Dong Jia; Bao-En Wang
Journal:  World J Gastroenterol       Date:  2008-05-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.